Session » T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Date: Monday, November 18, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1855

Identification of Autoreactive Cytotoxic T Cells in ANCA-Associated Vasculitis

10:30AM-12:30PM: Abstract Number: 1851

Aberrant Tfh Cells Generated by Th17 Cell Plasticity in the Gut Promote Autoimmune Arthritis

10:30AM-12:30PM: Abstract Number: 1837

Baseline Multiome Sequencing of CD45RO+CD45RA-CD4+ T Cell Reveals Distinct Immune Profiles Associated with Subsequent Response to Secukinumab Treatment

10:30AM-12:30PM: Abstract Number: 1861

CD8T Cells Depletion Promotes Human Tph/Tfh Cells Proliferation and Sjogren Syndrome Like Symptoms Without Graft versus Host Diseases in PBMC Transferred-humanized Mice

10:30AM-12:30PM: Abstract Number: 1848

Characterization of Treg Phenotype, Function and Its Transcriptome Signatures in Treatment-naïve Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1846

Citrullinated Vimentin-reactive Immune-regulatory CD4+CD39+TIGIThi T Cells Expand During Drug Free Remission in HLA-DR Shared-epitope+ ACPA+ Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1859

Clonal Relationships Between Tph and Tfh Cells in Patients with SLE and in Murine Lupus

10:30AM-12:30PM: Abstract Number: 1858

Co-modification of Citrullinated Proteins with Malondialdehyde-Acetaldehyde Leads to Amplified T Cell Responses and Increased Disease-specific Autoantibody Concentrations

10:30AM-12:30PM: Abstract Number: 1842

Development of Next Generation CAR T Cell Therapy for the Off-the-shelf Treatment of Autoimmune Diseases Without Conditioning Chemotherapy

10:30AM-12:30PM: Abstract Number: 1856

Distinct Proliferative and Special Properties of Peripheral Helper T Cells in RA Synovium

10:30AM-12:30PM: Abstract Number: 1850

Exhausted T-cells Are Increased in Autoimmune Diseases and Predict Response to Anti-TNF in RA and SPA Patients

10:30AM-12:30PM: Abstract Number: 1847

Expression Levels of the ATP-Gated Ion Channel P2RX7 Do Not Predict T Cell Sensitivity to Extracellular ATP and NAD

10:30AM-12:30PM: Abstract Number: 1862

Folate Receptor β CAR-Tregs Induce Monocyte Apoptosis and Immune Polarization: Potential for Therapeutic Application in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1835

FoxP3Hi CTLA4+ ICOS+ Regulatory T Cells Are Expanded in Patients with Sarcoidosis but Not Systemic Sclerosis or IgG4-Related Disease

10:30AM-12:30PM: Abstract Number: 1863

Human Endogenous Retroviruses Promote the Aberrant T Cell Differentiation in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1866

Identification of Sjögren’s Disease-Associated CD4+ T Cell Receptor (TCR) Motifs and Repertoire Landscape Through TCR Deep Sequencing

10:30AM-12:30PM: Abstract Number: 1843

Immune Responses to Herpes Zoster Vaccine Responses in Rheumatic Patients on JAK Inhibitors: Insights in Humoral and Cellular Response

10:30AM-12:30PM: Abstract Number: 1838

M5542: A Potent CD80, CD86, and OX40L Antagonist Fusion Molecule for the Treatment of Autoimmune Diseases

10:30AM-12:30PM: Abstract Number: 1844

Manufacturing of IMPT-514, a CD19/CD20 Bispecific CAR T Cell Product Candidate as a Potential Treatment of Patients with Autoimmune Diseases

10:30AM-12:30PM: Abstract Number: 1853

Mutated Nod2 Enhances Pathogenic Th17 Responses That Promote Experimental Blau Syndrome

10:30AM-12:30PM: Abstract Number: 1839

PPP2R3C Overexpression Suppresses TCR -mediated CD4+ T Cell Abnormal Activation in Systemic Lupus Erythematosus via JNK and AKT-mTOR Pathways

10:30AM-12:30PM: Abstract Number: 1841

Preclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases

10:30AM-12:30PM: Abstract Number: 1865

Reduction in CD4+T Cell Expression of CD28 and CD2 by Antibody-induced Internalization of CD6: A Potential Step Towards Immune Tolerance

10:30AM-12:30PM: Abstract Number: 1867

RNA Polymerase III Specific CD8+ T Cells at the Interface Between Scleroderma and Cancer

10:30AM-12:30PM: Abstract Number: 1864

S-4321, a Novel Dual-cell Bidirectional PD-1:FcγRIIb Selective Agonist Antibody for the Treatment of Autoimmune Disease

10:30AM-12:30PM: Abstract Number: 1849

Selective Targeting of One-Carbon Metabolism to Combat Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1840

Synovial Resident Memory T Cell Formation During Inflammation Requires Cell Contact with Fibroblast-Like Synoviocytes

10:30AM-12:30PM: Abstract Number: 1860

Targeting Th1 Effector Cytokines, TNF-α and IFN-γ, Attenuates Experimental Autoimmune Myeloperoxidase ANCA Associated Vasculitis

10:30AM-12:30PM: Abstract Number: 1854

TCR-Nck Modulators: Pioneering Oral Modulation of T Cell Receptor Activation Holding the Promise of Treating Autoimmune Diseases

10:30AM-12:30PM: Abstract Number: 1857

Thymic Mimetic Cells in Humans, Mice and Fish Are Evolutionarily Ancient with Species-specific Adaptations

10:30AM-12:30PM: Abstract Number: 1836

Transcriptional Changes in the Formation of Tissue Resident Memory T Cells in the Joint

10:30AM-12:30PM: Abstract Number: 1845

Treg Expansion and IL-6 Induced STAT3 Phosphorylation in CD4+ T Cells Is a Biomarker of Disease Flare in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1852

Uncovering a MAIT-Treg Axis in Skin UV Response: Implications for Photosensitive Reactions in Cutaneous Lupus Erythematosus

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].